XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Net Revenue $ 15,753,164 $ 9,670,778 $ 31,275,081 $ 17,482,001
Cost of goods sold 2,187,516 958,086 4,313,175 1,763,167
Gross profit 13,565,648 8,712,692 26,961,906 15,718,834
Operating expenses        
Selling, general and administrative expenses 13,811,476 10,428,133 26,780,545 19,803,763
Research and development 1,177,128 1,067,000 2,494,452 1,271,637
Depreciation and amortization 803,694 539,124 1,582,569 741,871
Change in fair value of earnout liabilities (360,470) 63,427 (813,157) 63,427
Total operating expenses 15,431,828 12,097,684 30,044,409 21,880,698
Operating loss (1,866,180) (3,384,992) (3,082,503) (6,161,864)
Other expense        
Interest expense and other (6)
Share of losses from equity method investment (379,633)
Total other expense (6) (379,633)
Loss before income taxes (1,866,180) (3,384,992) (3,082,509) (6,541,497)
Income tax benefit 4,141,906 4,141,906
Net income (loss) (1,866,180) 756,914 (3,082,509) (2,399,591)
Less: Net loss attributable to noncontrolling interest (38,447) (12,512) (76,876) (39,693)
Net income (loss) attributable to Sanara MedTech shareholders $ (1,827,733) $ 769,426 $ (3,005,633) $ (2,359,898)
Net income (loss) per share:        
Basic $ (0.22) $ 0.10 $ (0.37) $ (0.31)
Diluted $ (0.22) $ 0.09 $ (0.37) $ (0.31)
Weighted average common shares outstanding:        
Basic 8,226,271 7,791,431 8,200,173 7,699,422
Diluted 8,226,271 8,162,983 8,200,173 7,699,422